JAN 26, 2021
AAO 2020 Virtual
Retina/Vitreous, Vascular Disease
In this video from AAO 2020 Virtual, Dr. Rahul Khurana discusses highlights from his talk on the consequences of stopping treatment for wet AMD. The study included 434 eyes with at least 12 months of follow-up with suspended treatment after 12 weeks of inactivity. After 1 year, 41% of eyes showed recurrence; after 5 years, the rate of recurrence was 79%. Eyes that reactivated lost about 4 letters. Starting treatment again resulted in a 1-letter gain. Risk factors for reactivation included better vision at suspension (>20/40) and shorter duration of treatment (<3 years). In his clinical practice, Dr. Khurana remains very cautious about stopping treatment, and prefers to opt for indefinite fixed treatment intervals.
To learn more, watch Dr. Khurana's talk "Should We Ever Consider Stopping Treatment for Neovascular AMD?" during the AAO 2020 Virtual session, "Neovascular AMD" (RET11V).
Relevant Financial Disclosures: Dr. Khurana receives grant support from Roche and serves on the advisory board for Regeneron.